FLT3 antibody-based therapeutics for leukemia therapy.
Antibodies represent a unique class of therapeutics because of their high specificity toward a defined target antigen. Recent clinical success with antibody-based cancer therapeutics has led to an upsurge in the development of these agents. Antibodies directed against FLT3 represent a promising approach for the treatment of human leukemia. We discuss some basic aspects of antibody-based cancer therapeutics, including their mechanisms of action, with a focus on recent progress in the generation and development of anti-FLT3 antibodies as well as their therapeutic potentials in the treatment of human hematologic malignancies.
Li
Yiwen
Y
ImClone Systems Incorporated, New York, NY 10014, USA. Yiwen.li@imclone.com
Zhu
Zhenping
Z
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D018796:Immunoconjugates / Q000276:immunology / Q000627:therapeutic use; D007938:Leukemia / Q000188:drug therapy*; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors* / Q000276:immunology
D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3